PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 297 filers reported holding PACIRA PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 9.12 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,228,334 | -20.9% | 105,226 | +3.3% | 0.08% | -19.0% |
| Q2 2023 | $4,083,494 | +25.5% | 101,909 | +27.8% | 0.10% | +18.0% |
| Q1 2023 | $3,254,557 | +17.5% | 79,749 | +11.2% | 0.09% | +2.3% |
| Q4 2022 | $2,770,159 | -8.3% | 71,747 | +26.3% | 0.09% | -5.4% |
| Q3 2022 | $3,022,000 | -42.4% | 56,809 | -36.9% | 0.09% | -39.9% |
| Q2 2022 | $5,245,000 | -43.5% | 89,962 | -26.0% | 0.15% | -35.7% |
| Q1 2022 | $9,276,000 | +10.0% | 121,541 | -13.3% | 0.24% | +11.2% |
| Q4 2021 | $8,434,000 | +80.5% | 140,173 | +68.0% | 0.21% | +63.4% |
| Q3 2021 | $4,673,000 | +24.6% | 83,448 | +35.0% | 0.13% | +19.1% |
| Q2 2021 | $3,751,000 | -3.2% | 61,811 | +11.8% | 0.11% | -12.7% |
| Q1 2021 | $3,874,000 | +42944.4% | 55,277 | +26996.6% | 0.13% | – |
| Q4 2019 | $9,000 | +12.5% | 204 | 0.0% | 0.00% | – |
| Q3 2019 | $8,000 | -11.1% | 204 | 0.0% | 0.00% | – |
| Q2 2019 | $9,000 | – | 204 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |